5’-Azacitidine is a drug already approved for the treatment of acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS), including patients whose disease returned after having a stem cell transplant. However, it is unclear if 5’-azacitidine can prevent disease recurrence in patients who achieved remission after having an allogeneic (donated) stem cell transplant for AML or MDS.

The purpose of this study is to evaluate the safety and effectiveness of 5’-azacitidine for preventing recurrence in children and adults who are in remission after allogeneic stem cell transplantation for AML or MDS but who are at high risk of disease recurrence.